Tirzepatide
Tirzepatide (Mounjaro/Zepbound)
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It is a 39-amino acid synthetic peptide that produces significantly greater weight loss and glycemic control than selective GLP-1 agonists alone, with clinical trials demonstrating up to 20-22% mean body weight reduction over 72 weeks.
Mechanism of Action
Tirzepatide acts as a dual agonist at both GIP and GLP-1 receptors, triggering glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite via central hypothalamic signaling. The GIP receptor component enhances insulin sensitivity in adipose tissue and may reduce GLP-1-associated nausea, while GLP-1 receptor activation drives satiety signaling and further potentiates insulin secretion. The synergistic activation of both incretin pathways results in greater metabolic benefits than mono-agonism at equivalent doses.
Evidence by Health Goal(18 goals)
Dosing Protocols
Any time of day, consistent day each week; can be taken with or without food
Standard titration: 2.5mg weekly for 4 weeks, then increase by 2.5mg every 4 weeks as tolerated up to a maximum of 15mg/week. Subcutaneous injection into abdomen, thigh, or upper arm. Rotate injection sites. For compounded/research tirzepatide, reconstitute per vendor instructions and store refrigerated at 2-8°C.
Safety & Side Effects
Tirzepatide has a well-characterized safety profile from large Phase 3 trials but carries FDA black box warnings for thyroid C-cell tumor risk (contraindicated in personal or family history of medullary thyroid carcinoma or MEN2 syndrome); it is a prescription-only medication in all regulated markets and should not be used in type 1 diabetes or in individuals with a history of pancreatitis without physician oversight. Compounded tirzepatide from peptide vendors exists in a regulatory gray area and lacks the quality controls of FDA-approved formulations, introducing additional risks related to purity and dosing accuracy.
Possible Side Effects
- !Nausea (most common, affecting ~40-45% of users, typically worst during dose escalation)
- !Vomiting, particularly during initial weeks or after dose increases
- !Diarrhea or loose stools, often occurring early in treatment
- !Constipation, which may alternate with diarrhea
- !Decreased appetite and early satiety (therapeutic but can cause inadequate caloric intake)
- !Injection site reactions including erythema, pruritus, or mild induration
- !Fatigue and mild dizziness, especially during dose escalation
- !Hypoglycemia risk, primarily when used concurrently with insulin or sulfonylureas
Interactions
- -Insulin and sulfonylureas: significantly increases hypoglycemia risk; dose reduction of concomitant antidiabetic agents typically required
- -Oral contraceptives and other oral medications with narrow therapeutic windows: gastric emptying delay may reduce peak plasma concentration and absorption of co-administered oral drugs
- -Warfarin and other oral anticoagulants: altered GI transit and potential nausea-induced reduced food intake may affect INR stability; more frequent monitoring recommended
- -Alcohol: additive risk of hypoglycemia and exacerbation of GI side effects
- -Other GLP-1 receptor agonists (semaglutide, liraglutide): concurrent use contraindicated due to additive GI toxicity and unclear incremental benefit
Cost & Where to Buy
Brand-name Mounjaro/Zepbound retails at approximately $1,000-$1,300/month without insurance in the US; manufacturer savings cards can reduce this to $25-$550/month for eligible patients. Compounded tirzepatide from specialty pharmacies or research peptide vendors ranges from $150-$400/month depending on dose and source, though compounded versions lack FDA approval. Insurance coverage varies widely and prior authorization is commonly required.
Search on Amazon